Viridian Therapeutics (NASDAQ:VRDN) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Viridian Therapeutics (NASDAQ:VRDN) issued its earnings results on Tuesday. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16, FiscalAI reports. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The business’s revenue for the quarter was up 95.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.87) EPS.

Here are the key takeaways from Viridian Therapeutics’ conference call:

• REVEAL-2 met its primary endpoint — Q4 weekly elegrobart achieved a 50% proptosis responder rate vs 15% for placebo (Q8: 54%), with mean proptosis reductions of 1.88 mm (Q4) and 2.08 mm (Q8) versus 0.52 mm for placebo.
• The Q4 regimen produced a notable diplopia benefit in chronic TED, with a 61% diplopia response rate and 44% complete resolution, making elegrobart the first subcutaneous therapy to show a meaningful diplopia effect in pivotal phase III data.
• Safety was described as generally well-tolerated with most adverse events mild; hearing-impairment signals were low (placebo‑adjusted 4.1% Q4, 8.8% Q8), mainly tinnitus, with two mild hypoacusis cases that showed no detectable audiometric change and some resolution reported.
• Regulatory and development path accelerated — Viridian plans a BLA submission for elegrobart in Q1 2027, aims to launch a one‑step auto‑injector (as few as three at‑home doses), and expects veligrotug IV’s PDUFA on June 30.
• Management expects commercial upside and market expansion — they plan to leverage the veli + elegrobart portfolio, ~100 sales reps and physician/endocrinology outreach to grow the ~$2B TED market (management targets at least a doubling over time).

Viridian Therapeutics Trading Up 30.9%

Shares of NASDAQ VRDN traded up $4.35 during midday trading on Tuesday, hitting $18.41. 10,956,291 shares of the company traded hands, compared to its average volume of 2,079,966. Viridian Therapeutics has a 12-month low of $11.76 and a 12-month high of $34.29. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65. The stock has a 50-day moving average price of $22.20 and a 200 day moving average price of $27.05. The firm has a market cap of $1.90 billion, a P/E ratio of -5.61 and a beta of 0.82.

Analysts Set New Price Targets

VRDN has been the topic of a number of analyst reports. Royal Bank Of Canada decreased their price objective on shares of Viridian Therapeutics from $42.00 to $30.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 7th. Needham & Company LLC decreased their price objective on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Wall Street Zen cut shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Truist Financial decreased their price objective on shares of Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company decreased their price objective on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 31st. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $37.07.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VRDN. Larson Financial Group LLC purchased a new position in shares of Viridian Therapeutics during the third quarter valued at about $52,000. US Bancorp DE increased its position in shares of Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after buying an additional 463 shares during the period. Sei Investments Co. purchased a new position in shares of Viridian Therapeutics during the second quarter valued at about $147,000. Persistent Asset Partners Ltd purchased a new position in shares of Viridian Therapeutics during the fourth quarter valued at about $176,000. Finally, Creative Planning purchased a new position in shares of Viridian Therapeutics during the second quarter valued at about $179,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.